A national questionnaire survey of Japanese urologists on treatment perspectives for elderly prostate cancer patients

Abstract

ObjectiveThis study conducted a national questionnaire survey of Japanese urologists from a treatment perspective for older patients with prostate cancer.MethodsA questionnaire was distributed to 922 teaching hospitals of the Japanese Urological Association. Questionnaire items included years of urologist experience, gender, workplace, treatment equipment owned, daily specialty practice area, urological cancer specialty, treatment reference items for older adults, upper age limit for radical treatment, medication, and two hypothetical cases of Gleason grade group 2 prostate cancer with or without oligometastasis.ResultsIn total, 1732 questionnaires were analyzed, with responses evenly distributed across all age groups. Workplaces included general hospitals (49.4%), university hospitals (40.3%), and cancer centers (4.2%). Performance status was the most frequently mentioned treatment‐related item, followed by comorbidities and cognitive function. In addition, geriatric assessment was used by only 13.3% of respondents. No upper age limit was found for total prostatectomy, brachytherapy, and external beam radiation. Anti‐androgens, androgen receptor‐axis‐targeted agents, chemotherapy, poly ADP ribose polymerase inhibitors, and immune‐checkpoint inhibitors were selected by 6.8%, 35.6%, 47.3%, 89%, 62.8%, 24.7%, 41.9%, and 41.7% of the respondents, respectively. Response rates for administration of hormone therapy for hypothetical cases of Gleason grade group 2 prostate cancer with or without oligometastases were 96.8% and 61.2%, respectively.ConclusionsLess than 15% of urologists used geriatric assessments. Several responded that they would set age limits for highly invasive radical and systemic therapies.